Editas Medicine, Inc.(EDIT)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Editas Medicine, Inc. (EDIT) over the last 3 months consists of 28 total transactions. Among these, company executives and board members conducted 28 buys (totaling 110,868 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 110,868 shares, reflecting net buying interest with an estimated net acquisitions value of $2.14B.
28 insider transactions found. Showing 10 of 28 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| PARISON AMY | Chief Financial Officer | 678 | $1749.00 | Aug 3, 2026 |
| BURKLY LINDA | Officer | 4,928 | $13158.00 | Jul 28, 2026 |
| O NEILL GILMORE NEIL | Chief Executive Officer | 15,380 | $41543.00 | Jun 3, 2026 |
| BURKLY LINDA | Officer | 731 | $1975.00 | Jun 3, 2026 |
| PARISON AMY | Chief Financial Officer | 464 | $1253.00 | Jun 3, 2026 |
| O NEILL GILMORE NEIL | Chief Executive Officer | 5,394 | $10894.00 | Mar 3, 2026 |
| BURKLY LINDA | Officer | 749 | $1513.00 | Mar 3, 2026 |
| PARISON AMY | Chief Financial Officer | 474 | $957.00 | Mar 3, 2026 |
| O NEILL GILMORE NEIL | Chief Executive Officer | 5,603 | $12064.00 | Dec 3, 2025 |
| BURKLY LINDA | Officer | 713 | $1535.00 | Dec 3, 2025 |
Explore More Analysis for EDIT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.